A Phase 2 interventional study of LCQ908A and LCQ908A in Type 2 Diabetes Mellitus, sponsored by Novartis Pharmaceuticals. Completed at 67 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-09.
Sponsored by Novartis Pharmaceuticals · Phase 2, Interventional, and Treatment
This study will assess the effect of LCQ when added to metformin.
10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's enrollment of 693 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 229 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: LCQ908A · Drug: metformin
Drug: LCQ908A · Drug: metformin
Drug: LCQ908A · Drug: metformin
Drug: LCQ908A · Drug: metformin
Drug: LCQ908A · Drug: metformin
Drug: Placebo · Drug: metformin
Drug: Sitagliptin · Drug: metformin
Effect of LCQ on measures of glucose control
Time frame: 12 weeks
Changes in body weight and related measures
Time frame: 12 weeks
Insulin sensitivity
Time frame: 12 weeks
Safety and tolerability
Time frame: 12 weeks
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals